Literature DB >> 9804921

Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically.

J Oehlke1, A Scheller, B Wiesner, E Krause, M Beyermann, E Klauschenz, M Melzig, M Bienert.   

Abstract

Evidence that multiple, probably non-endocytic mechanisms are involved in the uptake into mammalian cells of the alpha-helical amphipathic model peptide FLUOS-KLALKLALKALKAALKLA-NH2 (I) is presented. Extensive cellular uptake of N-terminally GC-elongated derivatives of I, conjugated by disufide bridges to differently charged peptides, indicated that I-like model peptides might serve as vectors for intracellular delivery of polar bioactive compounds. The mode of the cellular internalization of I comprising energy-, temperature-, pH- and ion-dependent as well as -independent processes suggests analogy to that displayed by small unstructured peptides reported previously (Oehlke et al., Biochim. Biophys. Acta 1330 (1997) 50-60). The uptake behavior of I also showed analogy to that of several protein-derived helical peptide sequences, recently found to be capable of efficiently carrying tagged oligonucleotides and peptides directly into the cytosol of mammalian cells (Derossi et al., J. Biol. Chem. 269 (1994) 10444-10450; Lin et al., J. Biol. Chem. 270 (1995) 14255-14258; Fawell et al., Proc. Natl. Acad. Sci. USA 91 (1994) 664-668; Chaloin et al., Biochemistry 36 (1997) 11179-11187; Vives et al., J. Biol. Chem., 272 (1997) 16010-16017).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804921     DOI: 10.1016/s0005-2736(98)00161-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  64 in total

Review 1.  Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.

Authors:  Guillaume Drin; Christophe Rousselle; Jean-Michel Scherrmann; Anthony R Rees; Jamal Temsamani
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

3.  A critical reassessment of penetratin translocation across lipid membranes.

Authors:  Elsa Bárány-Wallje; Sandro Keller; Steffen Serowy; Sebastian Geibel; Peter Pohl; Michael Bienert; Margitta Dathe
Journal:  Biophys J       Date:  2005-07-22       Impact factor: 4.033

Review 4.  Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives.

Authors:  Leena N Patel; Jennica L Zaro; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2007-04-19       Impact factor: 4.200

Review 5.  Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.

Authors:  F Said Hassane; A F Saleh; R Abes; M J Gait; Bernard Lebleu
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

Review 6.  Antimicrobial peptides with cell-penetrating peptide properties and vice versa.

Authors:  Katrin Splith; Ines Neundorf
Journal:  Eur Biophys J       Date:  2011-02-19       Impact factor: 1.733

Review 7.  Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax.

Authors:  Kelsey Jensen; David Jasen WuWong; Sean Wong; Mieko Matsuyama; Shigemi Matsuyama
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-05

8.  Cell-penetrating Chaperone Peptide Prevents Protein Aggregation And Protects Against Cell Apoptosis.

Authors:  Murugesan Raju; Puttur Santhoshkumar; K Krishna Sharma
Journal:  Adv Biosyst       Date:  2017-11-13

9.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

Review 10.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.